Exhibit 99.2

New York NY, July 14, 2004 -- Manhattan Pharmaceuticals, Inc. ("Manhattan"
OTCBB: MHTT) released the results of the first human trial for its proprietary
lingual spray formulation of propofol, a Phase I safety, tolerability, and
pharmacokinetic study. Propofol, the world's leading intravenous anesthetic, is
being developed by Manhattan, in collaboration with Novadel Pharma Inc. (AMEX:
NVD), as a fast-acting, quick-recovery sedative for diagnostic and therapeutic
procedures.

The study, which took place in the United Kingdom, was a single-center,
randomized, double-blind, placebo-controlled dose-escalating study of propofol
lingual spray in twelve healthy adult volunteers. The primary objectives were to
compare the safety and tolerability of three dose levels of the propofol spray
to a single intravenous bolus low dose of propofol, as well as to determine the
respective pharmacokinetic profiles and relative bioavailability of the three
escalating doses.

No serious adverse events, nor dose-dependent changes in vital signs, occurred
in any group. The mean time to maximum blood concentration of propofol following
spray was approximately 30 min across all doses. Propofol was detectable in
blood as early as 4 minutes following spray administration. The mean maximum
blood concentrations plateaued at the highest of the three doses tested, and the
mean bioavailability of the current spray formulation was up to 18% of that of
the intravenous formulation.

 "The results of our first clinical trial support the feasibility of propofol
delivery by the oral mucosal route," observed Dr. Leonard Firestone, President
and CEO of Manhattan Pharmaceuticals. "This study is an important milestone for
the Company's product development program, whose aim is to give clinicians a
practical means by which to control the onset and depth of sedation that they
seek, to improve procedural outcomes as well as patient comfort and
satisfaction."

Physical characteristics and stability data for the formulation of Propofol LS
used in this trial was previously presented at the 19th Annual Meeting of the
Society for Ambulatory Anesthesia in Seattle in April 2004. Manhattan initiated
a joint development program for Propofol Lingual Spray with NovaDel Pharma, Inc.
in June 2003. On April 10, 2003, Manhattan announced that it had entered into a
License and Development Agreement with NovaDel Pharma Inc. for the worldwide,
exclusive rights to use NovaDel's proprietary lingual spray technology to
deliver propofol for preprocedural sedation.

About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (http://www.manhattanpharma.com/), a development
stage pharmaceutical company, acquires and develops proprietary prescription
drugs for large, underserved patient populations. In view of the worldwide
obesity epidemic, the Company is developing Oleoyl estrone, an orally
administered novel therapeutic for weight loss. To meet the needs of other
major, underserved medical markets, while lowering development risks, Manhattan
Pharmaceuticals also combines FDA-approved drugs with novel delivery
technologies and formulations. The Company is developing a convenient,
proprietary lingual spray formulation of propofol, the world's best-selling
general anesthetic, as a sedative-hypnotic for use during diagnostic and
therapeutic procedures.


<PAGE>

About NovaDel Pharma Inc.
NovaDel Pharma Inc.(http://www.novadel.com/) is a specialty pharmaceutical
company engaged in the development of novel drug delivery systems for
prescription and over-the-counter drugs. The Company's proprietary lingual spray
technology delivery system offers the patient (i) fast onset of action; (ii)
improved drug safety by reducing the required drug dosage and reducing side
effects; (iii) improved patient convenience and compliance; and (iv) enhanced
dosage reliability. The Company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.

Certain statements contained in this news release that are forward-looking in
nature are based on the current beliefs and assumptions of our management. When
used in this press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict," and similar
expressions and their variants may be used to identify forward-looking
statements. Such statements are valid only as of today, and we disclaim any
obligation to update this information. These statements are subject to known and
unknown risks and uncertainties that may cause actual future experience and
results to differ materially from the statements made. These statements are
based on our current beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk. Factors that might
cause such a material difference include, among others, uncertainties related to
the ability to attract and retain partners for our technologies, the
identification of lead compounds, the successful preclinical development
thereof, the completion of clinical trials, the FDA review process and other
governmental regulation, our pharmaceutical collaborator's ability to
successfully develop and commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third party reimbursement, and
other factors described in our filings with the Securities and Exchange
Commission